Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis

Anemia is a common complication of chronic kidney disease (CKD). Treating renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is effective but has side effects. Therefore, we performed a meta-analysis to assess the efficacy and safety of roxadustat in treating CKD-in...

Full description

Saved in:
Bibliographic Details
Published in:Aging (Albany, NY.) NY.), 2021-06, Vol.13 (13), p.17914-17929
Main Authors: Zhang, Li, Hou, Jie, Li, Jia, Su, Sen-Sen, Xue, Shuai
Format: Article
Language:English
Subjects:
Anemia - drug therapy
Anemia - etiology
Animals
Glycine - analogs & derivatives
Glycine - therapeutic use
Hematinics - therapeutic use
Hemoglobins - analysis
Hemoglobins - biosynthesis
Humans
Isoquinolines - therapeutic use
Renal Insufficiency, Chronic - complications
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anemia is a common complication of chronic kidney disease (CKD). Treating renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is effective but has side effects. Therefore, we performed a meta-analysis to assess the efficacy and safety of roxadustat in treating CKD-induced anemia. We searched publications online and conducted a meta-analysis and calculated relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences (MD) with 95% CIs for continuous data. Of 110 articles, nine were included that contained 12 data sets and 11 randomized control trials on roxadustat. In the non-dialysis-dependent (NDD) high-dose/low-dose subgroups, the change in hemoglobin (Hb) levels was significantly higher in the roxadustat group than in the placebo group (
ISSN:1945-4589
1945-4589
DOI:10.18632/aging.203143